NCT06104566View on ClinicalTrials.gov

Global Trial in APG2575 for Patients With CLL/SLL

PHASE3RecruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

December 20, 2023

Primary Completion Date

October 20, 2025

Study Completion Date

October 31, 2027

Conditions
CLL/SLL
Interventions
DRUG

lisaftoclax +BTK inhibitor

lisaftolax + BTK inhibitor

DRUG

BTK inhibitor

BTK inhibitor

Trial Locations (2)

77030

RECRUITING

MD Anderson Cancer Center, Houston

246007

RECRUITING

Kaluga Regional Clinical Research, Kaluga

Sponsors
All Listed Sponsors
lead

Ascentage Pharma Group Inc.

INDUSTRY

NCT06104566 - Global Trial in APG2575 for Patients With CLL/SLL | Biotech Hunter | Biotech Hunter